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a b s t r a c t
Opioids are the most effective analgesics for pain management, and efﬁcient pain control is a therapeutic
priority. Herein, we describe the synthesis and pharmacological activities of the 5-benzyl analogue of
the  opioid analgesic 14-methoxymetopon (14-MM). The result of the replacement of the 5-methyl
in 14-MM with a benzyl group on in vitro opioid receptor binding and functional proﬁles, and in vivo
behavioural properties, i.e. nociception and motor activity, was investigated. In rodent brain membranes,
the 5-benzyl derivative showed high afﬁnity at the  opioid receptor and decreased interaction with 
and  receptors, hence displaying a similar binding proﬁle as 14-MM. It displayed potent agonist activity
in vitro and in vivo. In in vitro guanosine-5′-O-(3-[35S]thio)-triphosphate ([35S]GTPS) binding assay, it
activated G-proteins in rat brain membranes through a  opioid receptor-mediated mechanism having
signiﬁcantly enhanced potency compared to DAMGO (d-Ala2,Me-Phe4,Gly-ol5]enkephalin), and to thentinociception
ain
otor impairment
 opioid agonist morphinans 14-MM, 14-O-methyloxymorphone (14-OMO) and morphine. In vivo, the
5-benzyl analogue of 14-MM elicited dose-dependent and naloxone-sensitive antinociceptive effects in
hot-plate and tail-ﬂick tests in mice after subcutaneous (s.c.) administration. Its analgesic potency was
comparable to 14-MM, and was 50-fold higher than that of morphine. Contrary to morphine, 14-MM
and 14-OMO, no motor dysfunction was produced by the new opioid in the mouse rotarod test at any
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. Introduction
Pain constitutes a major public-health problem with an enor-
ous impact on both the individual and the society. Debilitating
ain and particularly chronic pain is a constant backdrop to daily
ife, resulting in personal suffering, reduced work productivity and
ubstantial healthcare costs (Breivik et al., 2006; Marcus et al.,
009). Being a disabling symptom of many medical conditions,
ffective pain control is one of the most important therapeutic
riorities. Among analgesic drugs, opioids are the mainstay for
he management of moderate to severe pain (Inturrisi, 2002; Jain,
004; Benyamin et al., 2008). The opioid class of analgesics includes
everal clinically usedpain relieving agents suchasnaturally occur-
ing alkaloids (e.g. morphine, codeine), semisynthetic derivatives
e.g. oxycodone, oxymorphone, buprenorphine), and synthetic opi-
∗ Corresponding author. Tel.: +43 512 507 5248; fax: +43 512 507 2940.
E-mail address: Helmut.Schmidhammer@uibk.ac.at (H. Schmidhammer).
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Open access under CC BY-NC-ND license.y, the 5-benzyl analogue of 14-MM emerged as a novel potent  opioid
ced propensity to cause unwanted motor impairment.
© 2010 Elsevier B.V. 
ids (e.g. fentanyl, pethidine, tramadol). All these opioid drugs
s well as endogenous opioid peptides produce their biological
ctions by interactingwith three receptor types,,  and, belong-
ng to the family of G-protein-coupled receptors (GPCRs) (Knapp et
l., 1995; Kieffer and Evans, 2009).
Morphine and other opioids produce analgesia primarily
hrough their agonist action at the  opioid receptor, which is
he main type targeted for the pharmacotherapy of pain. How-
ver, currently used opioid analgesics also share a number of
evere side effects (e.g. respiratory depression, nausea, sedation,
izziness,motor disturbances and constipation),making their clin-
cal usefulness problematic and leading to early discontinuation,
nder-dosing and inadequate analgesia (Inturrisi, 2002; Jain, 2004;
enyaminet al., 2008). Increasingdrugdeaths fromopioids is a seri-
us issue (Benyamin et al., 2008). Considerable effort has therefore
Open access under CC BY-NC-ND license.een put forward to understand the appropriate use of opioid anal-
esics, while medicinal chemistry and opioid pharmacology have
een continuously engaged in the search for safer, more efﬁcacious
nd non-addicting opioid compounds, with the ﬁnal goal to reduce
omplications and to improve patient compliance.
126 M. Spetea et al. / European Journal of Pharm
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2Fig. 1. Structures of 14-OMO and 14-MM.
Our research in the morphinan class of opioid analgesics has
ed us to obtain a number of 14-alkoxymorphinan-6-ones that act
s effective antinociceptive agents in various animal models of
ain (Schmidhammer et al., 1984, 1990; Fürst et al., 1993, 2005;
reiner et al., 2003; Schütz et al., 2003; Spetea et al., 2004a,b,
005; Lattanzi et al., 2005; Al-Khrasani et al., 2007; Obara et al.,
007). Previous pharmacological reports described a derivative of
xymorphone, 14-O-methyloxymorphone (14-OMO, Fig. 1), which
ossesses about 40-fold higher antinociceptive potency than its
arent compound, and is up to 400-fold more potent than the ‘gold
tandard’ for pain therapy, morphine, in rodent models of acute
ociception, i.e. hot-plate test (Schmidhammer et al., 1984) and
ail-ﬂick test (Fürst et al., 2005; Riba et al., 2010), after subcuta-
eous (s.c.) administration. However, 14-OMO induces the typical
pioid side effects of the conventional  opioid analgesics includ-
ng constipation, respiratory depression and physical dependence
Schmidhammer et al., 1984; Lattanzi et al., 2005).
Further synthetic and pharmacologicalwork based on the intro-
uction of a methyl group at position 5 of 14-OMO gave rise to
4-methoxymetopon (14-MM,Fig. 1) (Schmidhammeret al., 1990),
potent and high afﬁnity  opioid receptor agonist in vitro (Fürst
t al., 1993; Spetea et al., 2003, 2004a; Mahurter et al., 2006).
n vivo, 14-MM retains the high antinociceptive potency of the
arent molecule and is considerably more active than morphine
n producing analgesia in diverse thermal, chemical and inﬂam-
atory pain models, after different routes of administration (s.c.,
ntraperitoneal, intracebroventricular and intrathecal) and in dif-
erent species (rats and mice) (Schmidhammer et al., 1990; Fürst
t al., 1993; Zernig et al., 2000; King et al., 2003; Urigüen et al.,
002; Greiner et al., 2003; Lattanzi et al., 2005; Bileviciute-Ljungar
t al., 2006; Riba et al., 2010). Itwas equipotent to sufentanil in elic-
ting analgesia in canines after intravenous administration (Freye
t al., 2000). Behaviour studies showed that 14-MM causes less
ronounced opioid adverse actions in terms of respiratory depres-
ion, hypotension, bradycardia, constipation, physical dependence,
ddiction potential and tolerance (Fürst et al., 1993; Freye et al.,
000; King et al., 2003; Király et al., 2006).
In view of these ﬁndings, we aimed in this study to investigate
he effect of the replacement of the 5-methyl group in 14-MMwith
benzyl substituent (compound 1, Fig. 2) on the pharmacological
roﬁle represented by in vitro opioid receptor binding and func-
ional activities, and in vivo behavioural properties, i.e. nociception
ndmotor function, after s.c. administration tomice. Consequently,
e have conducted a comparison of the pharmacological activ-
ties and physicochemical properties of compound 1 to those of
tructurally related opioid morphinans, 14-MM and 14-OMO, and
s
(
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f the clinically relevant morphine. Structure–activity relationship
SAR) studies in this class of opioid compounds based on substitu-
ion of the 5-methyl group in 14-MM with an arylalkyl group such
s benzyl may provide relevant information in the drug discovery
rocess for identiﬁcation of novel and safer analgesics towards the
reatment of pain.
. Materials and methods
.1. Materials
Thebaine was obtained from Tasmanian Alkaloids Ltd. (West-
ury, Tasmania, Australia). Melting points were determined on a
oﬂer melting point microscope (Reichert, Vienna, Austria) and
re uncorrected. 1H NMR spectra were recorded on a Varian Gem-
ni 200 (200MHz) spectrometer (Varian Inc., Palo Alto, CA, USA).
hemical shifts () are reported in ppm (relative to SiMe4 as inter-
al standard), coupling constants (J) in Hz. Mass spectra were
ecorded on a Finnigan Mat SSQ 7000 apparatus (Finnigan Mat,
an Jose, CA, USA). Elemental analysis was performed at the Insti-
ute of Physical Chemistry at the University of Vienna, Austria. For
hin layer chromatography (TLC), Polygram SIL G/UV254 precoated
lastic sheets (Macherey-Nagel, Germany) were used (eluent:
ethylene chloride/methanol/concentrated ammonia 90:9:1), and
or column chromatography, silica gel 60 (230–400 mesh ASTM,
luka, Switzerland) was used.
Opioid radioligands, [3H][d-Ala2,Me-Phe4,Gly-ol5]enkephalin
[3H]DAMGO), [3H]5,7,8-(-)N-methyl-N-[7-(1-pyrrolidinyl)-
-oxaspiro(4,5)dec-8-yl]benzeneacetamide ([3H]U69,593)
nd radiolabelled guanosine-5′-O-(3-[35S]thio)-triphosphate
[35S]GTPS) were purchased from PerkinElmer (Boston, MA,
SA). [3H][Ile5,6]deltorphin II was obtained from the Institute
f Isotopes Co. Ltd. (Budapest, Hungary). Naloxone hydrochlo-
ide (NX), Tris, unlabelled GTPS, guanosine diphosphate (GDP),
AMGO, d-Phe-Cys-Tyr-d-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP),
or-binaltorphimine (nor-BNI) and EGTA were obtained from
igma–Aldrich Inc. (St. Louis, MO, USA). Morphine hydrochloride
as obtained from Gatt-Koller GmbH (Innsbruck, Austria). 14-MM
Schmidhammer et al., 1990), 14-OMO (Schmidhammer et al.,
984) and naltrindole (NTI) (Portoghese et al., 1988a,b) were
repared at the Institute of Pharmacy, University of Innsbruck
Innsbruck, Austria) as previously described. All other chemicals
ere of analytical grade and obtained from standard commercial
ources.
.2. Animals
Sprague–Dawley rat and guinea pig brains used in in vitro
ssays were obtained from the Institut für Labortierkunde und
aborgenetik, Medizinische Universität Wien (Himberg, Aus-
ria). Male C57BL/6J mice (Institut für Labortierkunde und
aborgenetik, Medizinische Universität Wien, Himberg, Austria)
eighing 20–25g were used for in vivo studies. Mice were housed
n groups of ﬁve and were kept in a temperature-regulated envi-
onment under a controlled 12h light/dark cycle with free access
o food and water at all times except during testing. All animal
xperiments were approved by the Austrian Ethical Commission.
.3. Synthetic proceduresThe 5-benzyl substituted morphinans 1, 3 and 4 were synthe-
ized as illustrated in Fig. 2. Thus, 5-benzyl-14-hydroxycodeinon
2) prepared from thebaine via 5-benzylthebaine (Gates et al.,
989) was 14-O-methylated with dimethyl sulfate in the presence
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oig. 2. Reaction scheme for the synthesis of 5-benzyl substituted morphinans. Reag
iii) 48% HBr, reﬂux.
f sodiumhydride inN,N-dimethylformamide to afford 5-benzyl-
4-methoxycodeinone (3) as a yellow-brown oil. Part of this oil
as used for the next synthetic step without further puriﬁcation
hile another part was puriﬁed by column chromatography and
ubsequently converted into the hydrochloride salt 3·HCl. Catalytic
ydrogenation of 3 in methanol over 10% Pd/C at room tempera-
ure gave compound 4. The 3-O-methyl ether of compound 4 was
leaved by reﬂuxing in 48% hydrobromic acid to obtain phenol 1.
he base was converted into the hydrochloride salt 1 HCl.
.3.1. 5ˇ-Benzyl-14-methoxycodeinone hydrochloride (=5-
enzyl-7,8-didehydro-4,5˛-epoxy-3,14ˇ-dimethoxy-17-methyl-
orphinan-6-one hydrochloride) (3·HCl)
Sodium hydride (1.2 g, 50mmol) (obtained from 2.0 g 60%
odium hydride dispersion in oil by washings with petroleum
ther) was added to a stirred solution of 5-benzyl-14-
o
b
c
y
tnd conditions: (i) NaH, (CH3O)2SO2, DMF, 0 ◦C; (ii) 10% Pd/C, H2, MeOH, 30psi, r.t.;
ydroxycodeinone (2) (Gates et al., 1989) (7.95g, 19.7mmol)
n 100ml anhydrous N,N-dimethylformamide under nitrogen at
◦C (bath temperature). After 15min, dimethyl sulfate (2.43ml,
5.6mmol) was added and the mixture was stirred for 1h at 0 ◦C
bath temperature). Excess sodium hydride was destroyed care-
ully by addition of small pieces of ice. Then the mixture was
iluted with water (250ml) and extracted with methylene chlo-
ide (3×100ml); the combined organic layers were washed with
ater (1×100ml, 3×60ml) and brine (100ml), dried (sodium
ulfate), and evaporated to give 8.3 g of a yellow-brown colored
il. Part of this oil was used for the next synthetic step with-
ut further puriﬁcation while 500mg of this oil were puriﬁed
y column chromatography (silica gel, elution with methylene
hloride/methanol/concentrated ammonia, 250:2:0.5) to afford a
ellowish oil (210mg). The hydrochloride salt was obtained in
he usual way (diethyl ether/HCl) to yield 148mg of 3·HCl: mp
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64–166 ◦C; IR (KBr): 1680 (CO) cm−1; 1H NMR (DMSO-d6): ı 9.47
s, broad, +NH), 7.37–7.09 (m, 5 arom. H), 7.04 (d, 1 H, C8–H,
=10.0Hz), 6.84 (d, 1 arom. H, J=8.4Hz), 6.74 (d, 1 arom. H,
= 8.4Hz), 6.29 (d, 1 H, C7–H, J=10.0Hz), 3.76 (s, 3 H, C3–OCH3),
.59 (d, 1 H, C5–CH2, J=15.1Hz), 3.37 (s, 3 H, C14–OCH3), 3.29 (d,
H, C5–CH2), J=15.1Hz), 2.88 (d, 3 H, +NCH3, J=4.6Hz); MS (CI):
/z 418 (M++1). Anal. Calcd for C26H27NO4·HCl·0.9 H2O: C 66.42, H
.39, N 2.98. Found: C 66.16, H 6.45, N 2.91.
.3.2. 5ˇ-Benzyl-4,5˛-epoxy-3,14ˇ-dimethoxy-17-
ethylmorphinan-6-one
4)
A mixture of the yellow-brown colored oil of 3 (6.96 g,
6.7mmol), 0.7 g 10% Pd/C-catalyst and 150ml of methanol was
ydrogenated at room temperature and 30psi for 3h. Then the cat-
lyst was ﬁltered off and the ﬁltrate was evaporated. The residue
slightly brown foam) was crystallized from isopropanol to yield
.14 g (45%) pure 4: mp 136–138 ◦C; IR (KBr): 1725 (CO) cm−1;
H NMR (CDCl3): ı 7.35–7.18 (m, 5 arom. H), 6.66 (d, 1 arom. H,
= 8.2Hz), 6.57 (d, 1 arom. H, J=8.2Hz), 3.90 (s, C3–OCH3), 3.53 (d,
H, C5–CH2, J=14.7Hz), 3.43 (d, 1 H, C5–CH2, J=14.7Hz), 3.34 (s,
14–OCH3), 2.42 (s, NCH3); MS (CI): m/z 420 (M++1). Anal. Calcd for
26H29NO4·0.3 iPrOH: C 73.84, H 7.23, N 3.20. Found: C 73.95, H
.99, N 3.26.
.3.3. 5ˇ-Benzyl-4,5˛-epoxy-3-hydroxy-14ˇ-methoxy-17-
ethylmorphinan-6-one hydrochloride
1·HCl)
A solution of 4 (2.90 g, 6.9mmol) in 40ml of 48% hydrobromic
cid was reﬂuxed for 15min and then evaporated. The residue
as dissolved in methanol and again evaporated. The resulting
oam (2.50g) was converted into the base which was puriﬁed
y column chromatography (silica gel, elution with methylene
hloride/methanol/concentrated ammonia, 250:3:0.5) to afford a
ellow oil (2.27 g). The hydrochloride salt was obtained in the
sual way (diethyl ether/HCl) to yield 2.30g (75%) of 1·HCl: mp
22–224 ◦C; IR (KBr): 1725 (CO) cm−1; 1H NMR (DMSO-d6): ı 9.45
s, OH), 9.38 (s, broad, +NH), 7.37–7.09 (m, 5 arom. H), 6.70 (d, 1
rom.H, J=8.2Hz), 6.62 (d, 1 arom.H, J=8.2Hz), 3.41 (s, C14-OCH3),
.89 (d, 3 H, +NCH3, J=3.4Hz); MS (CI): m/z 406 (M++1). Anal. Calcd
or C25H27NO4·HCl·1.2 H2O: C 64.77, H 6.61, N 3.02. Found: C 65.05,
6.44, N 2.99.
.4. In vitro assays
.4.1. Brain membrane preparations
Membranes were prepared from Sprague–Dawley rat or guinea
ig brains as previously described (Spetea et al., 2003). Brainswith-
ut cerebella were homogenized on ice in 5 volumes/weight of
ce-cold 50mM Tris–HCl buffer (pH 7.4) and diluted in 30 vol-
mes/weight of the same buffer. After centrifugation at 40,000× g
or 20min at 4 ◦C, the pellets were resuspended in 30 vol-
mes/weight of 50mM Tris–HCl buffer (pH 7.4) and incubated
t 37 ◦C for 30min. The centrifugation step described above was
epeated, the ﬁnal pellets were resuspended in 5 volumes/weight
f 50mM Tris–HCl buffer (pH 7.4) containing 0.32M sucrose and
tored at −80 ◦C until use. Protein concentration was determined
y themethod of Bradford using bovine serumalbumin as standard
Bradford, 1976)..4.2. Opioid receptor binding assays
Binding experiments were performed in 50mM Tris–HCl buffer
pH 7.4.) in a ﬁnal volume of 1ml containing 0.3–0.5mg pro-
ein and at least 10 concentrations of test compound as described
Spetea et al., 2003). Rat brain membranes were incubated either
t
l
T
raceutical Sciences 41 (2010) 125–135
ith [3H]DAMGO (1nM, 45min, 35 ◦C) or [3H][Ile5,6]deltorphin
I (0.5nM, 45min, 35 ◦C). Guinea pig brain preparations were
ncubated with [3H]U69,593 (1nM, 30min, 30 ◦C). Reactions
ere terminated by rapid ﬁltration through Whatman GF glass
ber ﬁlters type GF/B pre-soaked in 0.1% polyethylenimine for
h at 4 ◦C for [3H]U69,593, or type GF/C for [3H]DAMGO and
3H][Ile5,6]deltorphin II) using a Brandel M24R Cell Harvester
Gaithersburg,MD,USA). Filterswerewashed three timeswith5ml
f ice-cold 50mM Tris–HCl buffer (pH 7.4). Non-speciﬁc binding
as determined in the presence of 10M naloxone. The bound
adioactivity was measured by liquid scintillation counting using
Beckman CoulterTM LS6500 (Beckman Coulter Inc., Fullerton, CA,
SA).
Inhibition constant (Ki) values were calculated from competi-
ion binding curves using the non-linear least-square curve ﬁtting
y GraphPad Prism software (v3; GraphPad Software Inc., San
iego, CA, USA). All experiments were performed in duplicate and
epeated two to six times.
.4.3. [35S]GTPS (guanosine-5′-O-(3-[35S]thio)-triphosphate)
inding assay
Rat brain membranes (10g of protein) were incubated for
0min at 30 ◦C in Tris-EGTA buffer (50mM Tris–HCl buffer, 3mM
gCl2, 1mM EGTA, 100nM NaCl, pH 7.4) containing 30M GDP,
.05nM [35S]GTPS and appropriate concentrations of test com-
ound in a ﬁnal volume of 1ml as previously described (Spetea
t al., 2003). Non-speciﬁc binding was measured in the presence
f 100M unlabelled GTPS. Reactions were terminated by vac-
um ﬁltration through Whatman GF/B glass ﬁber ﬁlters and bound
35S]GTPS retained on the ﬁlters was determined as described for
pioid receptor binding assays.
Stimulation of [35S]GTPS binding produced by the test com-
ound is given as percentage of the basal activity (deﬁned as 100%,
easured in the absence of test compound). The EC50 (nM, con-
entration of ligand to elicit half-maximal effect) and Emax (%,
aximum stimulation)were calculated using nonlinear regression
nalysis and sigmoidal curve ﬁtting with the GraphPad Prism soft-
are. All experiments were performed in triplicate and repeated
t least three times.
.5. In vivo testing
.5.1. Drug administration
Vehicle (saline) or solutions of test compounds prepared in ster-
le physiological saline (0.9%) were administered s.c. to mice in a
olume of 10l per 1 g body weight.
.5.2. Nociceptive assessments
Hot-plate latencies are determined as described (Lattanzi et al.,
005) by placing each mouse on a TSE hot plate V2.0 plate (TSE
ystem Inc., Midland, MI, USA) kept at 55 ◦C and observing the
ccurrence of a nociceptive response (licking of a hind paw, jump-
ng). To conﬁne the mice to a certain observation area, a colourless
lastic cylinder of 20 cm diameter was placed on the hot-plate. In
rder to avoid possible tissue injury, a cut-off time of 12 swas used.
The tail-ﬂick test was performed using an UB 37360 Ugo Basile
nalgesiometer (UgoBasile s.r.l., Varese, Italy) asdescribed (Greiner
t al., 2003). The reaction time required by the mouse to remove its
ail due to the radiant heat was measured and deﬁned as the tail-
ick latency. A cut-off time of 10 s was used in order to minimize
issue damage.
Hot-plate and tail-ﬂick latencies were measured before (basal
atency, BL) and 30min after drug s.c. administration (test latency,
L). For establishing the dose–response effect, the antinociceptive
esponse was expressed as percent of Maximum Possible Effect
harmaceutical Sciences 41 (2010) 125–135 129
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%MPE) = [(TL−BL)/(cut-off time−BL)]×100 for each dose tested.
ach experimental group included ﬁve mice. ED50, deﬁned as the
pioid dose that produced an analgesic effect equal to 50% MPE,
nd 95% conﬁdence limits were calculated using linear regression
ccording to the method of Litchﬁeld and Wilcoxon (1949).
.5.3. Motor activity
The drug effect on motor coordination was tested in the rotarod
est using an accelerating rotarod treadmill (Acceler Rota-Rod
650, Ugo Basile s.r.l., Varese, Italy) for mice (diameter 3.5 cm)
Jones and Roberts, 1968). The treadmill was accelerated from 4
o 40 rpm over a period of 5min, and the time spent on the drum
as recorded for each mouse. A 300 s cut-off time was used. Mice
ere evaluated prior to and 30min after drug or vehicle (saline)
.c. administration. Each experimental group included ﬁve ani-
als. Percentage (%) changes from the rotarod latencies obtained
efore (BL) and after drug administration (TL) were calculated as:
(TL−BL)/(300 s−BL)]×100.
.6. Determination of physicochemical properties
Lipophilicity of opioid compounds was evaluated at 25 ◦C by
etermination of partition (logP) and distribution coefﬁcients
logD) in an immiscible (biphasic) octanol/watermediumusing the
CA200/Cheqsol instrument (SiriusAnalytical Instruments, Sussex,
K) as described (Riba et al., 2010). The instrument was stan-
ardized by a four-parameter method as described (Avdeef, 1993).
itrations of the sample solutions having volumes between 6 and
0ml and molarity between 0.5 and 2.5mM were started at pH
.8 (using 0.5M HCl) and ﬁnished at pH 12.2 (using 0.5M KOH).
ll titrations were performed in 0.15M KCl solution under argon
as. The ionization constant (pKa, pH at 50% ionization of the com-
ound) was determined by the shape of the titration curve and
artitioncoefﬁcientsweredeterminedby theshift in titrationcurve
fpKa in thepresenceofoctanol. Theanalysis ofpH-metricdatawas
erformed by ReﬁnementPro software (v2.0, Sirius, Sussex, UK).
.7. Statistical analysis
All data are reported as mean± SEM. Statistical analysis was
arried out using one-way analysis of variances (ANOVA), and
omparisons among groups were performed by the independent
-test using SPSS software (v15.0; SPSS Inc., Chicago, IL, USA). A p
alue <0.05 was considered statistically signiﬁcant.
. Results
.1. In vitro opioid receptor binding afﬁnities
Binding afﬁnities of compounds 1, 3 and 4 (Fig. 2) at opi-
id receptors were determined in vitro using competition binding
ssays in rat brain (, ) and guinea pig brain ()membrane prepa-
ations, andemploying [3H]DAMGO(), [3H][Ile5,6]deltorphin II ()
nd [3H]U69,593 () as speciﬁc opioid radioligands (Spetea et al.,
003). The ,  and  opioid receptor binding afﬁnities expressed
s inhibition constants (Ki) are summarized in Table 1. For compar-
son purposes, the opioid binding afﬁnity data for 14-MM (Spetea
t al., 2003), 14-OMO (Spetea et al., 2004a) and morphine (Spetea
t al., 2003) are included.
In in vitro binding assays, compound 1 was shown to bind with
igh afﬁnity at the  opioid receptor (Ki = 0.31nM), and with two
rders of magnitude lower afﬁnities at  and  receptors (13.1
nd 22.8nM, respectively), hence displaying a comparable bind-
ng proﬁle as the parent compound 14-MMand its 5-unsubstituted
nalogue 14-OMO (Table 1). Compound 1 exhibited about 20-fold
a
G
w
e
(ig. 3. Concentration-dependent stimulation of [ S]GTPS binding by compound
, and 14-MM, 14-OMO, morphine and DAMGO in rat brain membranes. Data
re shown as % stimulation over basal [35S]GTPS binding and represent the
ean± SEM of at least three independent experiments, all performed in triplicate.
nhanced afﬁnity at the  receptor in comparison to morphine
Ki = 6.55nM). The other two 5-benzyl substituted derivatives (3
nd 4) showed moderate afﬁnity at the  opioid receptor (Kis of
4.1 and 65.4nM, respectively) and signiﬁcantly reduced interac-
ion with  and  receptors (Table 1).
.2. In vitro stimulation of [35S]GTPS binding
The effect of the 5-benzyl analogue 1 on G-protein activation
as evaluated using the ligand-stimulated [35S]GTPS binding
ssay in rat brain membranes (Spetea et al., 2003). Its stimulatory
ffect was compared with that of 14-MM, 14-OMO, morphine and
he prototype  opioid receptor agonist DAMGO.
As shown in Fig. 3, compound 1, 14-MM, 14-OMO, mor-
hine and DAMGO produced concentration-dependent increase
n [35S]GTPS binding. Agonist potencies (ED50) and maximal
esponse (Emax) values were determined and are listed in Table 2.
he rank order of potencies in stimulating [35S]GTPS bindingwas:
ompound 1>14-OMO>14-MM>DAMGO>morphine. The mean
aximal response was higher for 14-MM and 14-OMO and some-
hat lower for compound 1 and morphine than that of DAMGO.
Compound 1 was shown to be the most potent agonist with
n ED50 value of 13.7nM, whereas its parent compound 14-MM
ad a potency of 63nM in stimulating [35S]GTPS binding in rat
rain membranes. It displayed a comparable efﬁcacy to morphine,
ut it was less efﬁcacious than DAMGO, 14-MM and 14-OMO
Table 2). Also, 14-OMO activated G-proteins as indicated by the
oncentration-dependent increases in [35S]GTPS binding (Fig. 3)
howing a signiﬁcantly increased agonist potency (ED50 =23.7nM)
han 14-MM and DAMGO, while exhibiting comparable efﬁcacy
Table 2).
In order to assess the speciﬁcity of G-protein activation via
pioid receptors by compound 1, agonist-stimulated [35S]GTPS
inding was probed with the opioid antagonist naloxone. Similar
o 14-MM, 14-OMO and DAMGO, the increase of [35S]GTPS bind-
ng produced by compound 1 (1M) was prevented by naloxone
1M) (Fig. 4).
Furthermore, to establish the  opioid receptor speciﬁcity of
timulated [35S]GTPS binding by compound 1, we examined the
bility of type selective opioid receptor antagonists to reverse the
-protein activating effects (Fig. 4). [35S]GTPS binding assays
ere conducted by incubation of compound 1 (1M) in the pres-
nce and absence of selective antagonists acting at the  (CTAP)
Kramer et al., 1989),  (NTI) (Portoghese et al., 1988a,b) or  (nor-
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Table 1
Binding afﬁnities of investigated opioid compounds at ,  and  opioid receptors.
Ki (nM)a
[3H]DAMGO ()b [3H][Ile5,6]deltorphin II ()b [3H]U69,593 ()c
1 0.31±0.02 13.1±1.7 22.8±0.3
3 34.1±6.0 >10,000 1894±453
4 65.4±2.9 >10,000 4414±1229
14-MMd 0.15±0.01 13.3±0.2 25.2±4.9b
14-OMOe 0.10±0.01 4.80±0.22 10.2±2.0b
Morphined 6.55±0.74 217±19 113±9b
a Values are the mean± SEM of 2–6 independent experiments, all performed in duplicate.
b Rat brain membranes were used.
c Guinea brain membranes were used.
d Data from Spetea et al. (2003).
e Data from Spetea et al. (2004a).
Fig. 4. Effect of the non-selective opioid antagonist naloxone (NX), and of selective  (C
s
D
r
T
S
r
ftimulated by compound 1, 14-MM, 14-OMO and DAMGO in rat brain membranes. Assa
AMGO alone or in the presence of NX (1M), CTAP (1 and 10M), NTI (10nM) and nor
epresent the mean± SEM of at least three independent experiments, all performed in tri
able 2
timulation of [35S]GTPS binding in response to investigated opioid compounds in
at brain membranes.
ED50 (nM)a Emax (%)a
1 13.7±2.6d 158±2c
14-MM 63.0±6.3d,g 203±13f
14-OMO 23.7±2.0d,e 199±5f
Morphine 462±42f 157±6b
DAMGO 309±35 185±4
a Values are the mean± SEM of at least three independent experiments, all per-
ormed in triplicate.
b p<0.05.
c p<0.01.
d p<0.001 vs. DAMGO.
e p<0.05.
f p<0.01.
g p<0.001 vs. compound 1.
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vTAP),  (NTI) and  (nor-BNI) opioid receptor antagonists on [35S]GTPS binding
ys were performed in the presence of 1M of compound 1, 14-MM, 14-OMO or
-BNI (100nM). Data are shown as % stimulation over basal [35S]GTPS binding and
plicate. ***p<0.001 vs. agonist alone.
NI) (Portoghese et al., 1987) opioid receptors. As shown in Fig. 4,
he increase of [35S]GTPS binding by compound 1 was reversed
y co-incubationwith CTAP in a concentration-dependentmanner.
s well, CTAP has caused antagonism of stimulatory actions pro-
uced by either 1M of 14-MM, 14-OMO or DAMGO. Conversely,
TI (10nM) andnor-BNI (100nM)hadno signiﬁcant effect on com-
ound 1-stimulated [35S]GTPS binding, as also observed with the
theropioid agonists, 14-MM, 14-OMOandDAMGO (Fig. 4). Con-
entrations of antagonists, CTAP, NTI and nor-BNI, were chosen
ased on observations that the corresponding agonist-stimulated
35S]GTPS binding, i.e. DAMGO () (Fig. 4), SNC80 () andU69,593
) (data not shown), respectively, was selectively inhibited by the
ntagonist..3. Antinociceptive effects in mice after s.c. administration
Following in vitro studies, compound 1 was investigated in
ivo for the antinociceptive properties in mice after s.c. admin-
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Fig. 5. Right panel: Dose-dependent antinociceptive effect induced after s.c. administration by compound 1, 14-MM, 14-OMO and morphine in the (A) hot-plate test and
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tB) tail-ﬂick test in mice. Left panel: Antagonism by naloxone (NX) on the antinocic
B) tail-ﬂick test. NX (1mg/kg) was s.c. injected to mice 10min before s.c. administr
ompound 1 alone. Hot-plate or tail-ﬂick latencies (as %MPE) were determined 30m
ve mice per experimental group. ***p<0.001 vs. saline control group; ###p<0.001
stration using hot-plate (Lattanzi et al., 2005) and tail-ﬂick tests
Greiner et al., 2003), and its activity was compared to that of 14-
M, 14-OMO and morphine (Fig. 5). Antinociceptive ED50 values
nd 95% conﬁdence limits were calculated and are presented in
able 3.
As shown in Fig. 5, compound 1 produced dose-dependent
ntinociceptive effects after systemic s.c. administration to mice
n both nociceptive tests. The antinociceptive dose necessary to
licit a 50% effect was 0.053mg/kg in the hot-plate test, and a sim-
lar ED50 value of 0.043mg/kg was determined in the tail-ﬂick test.
ompared to morphine, compound 1 showed more than 50-fold
ncreased analgesic potency (Table 3). In line with previous reports
Zernig et al., 2000; King et al., 2003; Greiner et al., 2003; Lattanzi
t al., 2005; Riba et al., 2010), 14-MM was found to be 80-fold
ore potent than morphine in both thermal nociceptive assays in
ice following s.c. administration. Similarly, s.c. 14-OMOexhibited
ver 150-fold enhanced antinociceptive potency thanmorphine, in
able 3
ntinociceptive potencies in mice after s.c. administration.
ED50 (mg/kg, s.c.)a
Hot-plate test Tail-ﬂick test
1 0.053 (0.033–0.066) 0.043 (0.025–0.073)
14-MM 0.028 (0.014–0.058) 0.028 (0.017–0.047)
14-OMO 0.017 (0.012–0.025) 0.014 (0.010–0.019)
Morphine 2.63 (1.55–4.39) 2.29 (1.31–3.80)
a Values in parenthesis are 95% conﬁdence limits.
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oeffect of compound 1 in mice after s.c. administration in the (A) hot-plate test and
of compound 1 (0.1mg/kg). Other groups of mice received s.c. injection of saline or
ter s.c. administration of the opioid agonist. Data are shown as the mean± SEM of
pound 1-treated group.
greement with earlier ﬁndings in rodents (Schmidhammer et al.,
984; Fürst et al., 2005; Lattanzi et al., 2005; Riba et al., 2010).
To investigatewhether theantinociceptiveactionsof compound
are mediated through opioid receptor interactions, we examined
he effect of pre-treatment with the opioid antagonist naloxone
n mice that subsequently received compound 1. As illustrated in
ig. 5, s.c. dosing of mice with compound 1 (0.1mg/kg) produced
igniﬁcant increases in both hot-plate and tail-ﬂick responses,
hich were reversed by naloxone injected 10min before the
gonist (1mg/kg, s.c.) to exhibit similar values as elicited by saline-
reated animals.
.4. Effect on motor coordination in mice after s.c. administration
Further in vivo pharmacological studies were performed with
ompound 1 by assessing its effect on motor coordination in mice
fter s.c. administration using the rotarod test. The potential to
epress motor activity was compared to that of morphine, 14-MM
nd 14-OMO.
Dose-dependent drug effects onmotor performance induced by
ompound 1, 14-MM, 14-OMO andmorphine in themouse rotarod
est are shown in Fig. 6. Thehighest testeddose in the rotarod assay,
hich produced maximum MPE% values (i.e. 100%) in antinoci-
eption, was selected. Compound 1 provoked no changes in the
ormal behaviour of mice as demonstrated in rotarod experiments
n which no signiﬁcant alterations in the rotarod latencies were
bserved over the dose range of 0.025–0.2mg/kg. A signiﬁcant
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aig. 6. Effect of opioid compounds on the motor performance in mice as measured u
r test compound, and the time the animals remain on the device until falling was r
nd each value represents the mean± SEM of ﬁve mice per experimental group. **p
ecrease inmotor coordination compared to saline-treated control
icewas recorded after s.c. administration of the opioid agonists
4-MM at 0.1mg/kg and 14-OMO at 0.06mg/kg (Fig. 6). Also, sys-
emic morphine affected rotarod performance over the dose range
f 1.25–10mg/kg with a signiﬁcant effect after the 10mg/kg dose.
.5. Physicochemical properties
The ionization constants for compound 1 were determined
n three independent assays performed at 25 ◦C. The pKa val-
es for the amine function and the phenolic hydroxyl group,
nd the value of the octanol–water partition coefﬁcient, logP, a
uantitative descriptor of lipophilicity are presented in Table 4.
ecently reported physicochemical properties of 14-MM, 14-OMO
nd morphine (Riba et al., 2010) are included for comparison.
s shown in Table 4, the 5-benzyl derivative of 14-MM exhib-
ted higher lipophilicity (logP=1.49) than its parent compound
logP=1.12) and an even larger increase when compared to
4-OMO (logP=0.60). Also, higher values for the distribution coef-
able 4
onization constants and octanol–water partition (logP) and distribution (logD)
oefﬁcients of opioid morphinans at 25 ◦C.
Compound pKa (amine) pKa (phenol) logP logD (pH 7.4)
1 8.13±0.04 9.40±0.06 1.49±0.06 0.69±0.13
14-MMa 8.36 9.39 1.12 0.11
14-OMOa 8.18 9.21 0.60 −0.25
Morphinea 8.15 9.29 0.88 0.06
alues are the mean± SEM of three independent experiments.
a Data from Riba et al. (2010).
a
l
s
1
r
t
1
a
b
w
s
a
t
5
ehe rotarod test. Mice were tested 30min after s.c. administration of saline (control)
d. Data are shown as percentage from basal latencies (before drug administration)
, ***p<0.001 vs. saline-treated control group.
cient, logD at pH 7.4, was determined for compound 1 than for
4-MM and 14-OMO as well as morphine.
. Discussion
In the present study, we have shown by in vitro binding and
unctional assays compiled with in vivo behavioural approaches
hat replacement of the methyl group in position 5 in 14-MM with
benzyl substituent leads to qualitative and quantitative differ-
nces in the interaction with opioid receptors. The results indicate
hat the 5-benzyl analogue of 14-MM, compound 1, exhibits high
fﬁnity and potent agonism at the  opioid receptor and shows
ntinociceptive efﬁcacy through opioid receptor-mediated mech-
nisms achieved at doses that had no signiﬁcant effect on motor
ctivity.
Following the pattern of SAR, the in vitro and in vivo pharmaco-
ogical proﬁle shownby the investigated opioid ligands is related to
peciﬁc structural features. Substitution of the 5-methyl group in
4-MM with a benzyl group left binding afﬁnities at  and  opioid
eceptors essentially unchangedwhile retaining the high afﬁnity at
he receptor (Ki of 0.15nM for 14-MM vs. 0.31nM for compound
). The assessment of binding afﬁnities of 14-OMO and its 5-benzyl
nalogue 1 revealed that the introduction of an arylalkyl group, i.e.
enzyl at position 5, maintained the high afﬁnity at the receptor,
ith only a minor decrease in afﬁnities at  and  receptors, hencetill displaying  opioid receptor selectivity. These data conﬁrm
nd extend previous SAR observations in terms of opioid recep-
or binding in this series of opioid compounds, when comparing
-unsubstituted to their 5-methyl substituted analogues (Spetea
t al., 2004a; Lattanzi et al., 2005).
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When examining the in vitro opioid binding proﬁle of com-
ound 1 and its 3-methoxy analogue 4, it became apparent
hat the presence of a methoxy group at position 3 has a
ajor effect on binding afﬁnities to all three opioid recep-
or types. The present observations on the detrimental effect
n the interaction with opioid receptors upon substitution at
he 3-hydroxy group in the morphinan skeleton support ear-
ier reports (Beyerman et al., 1976; Pasternak et al., 1987; Chen
t al., 1991; Mignat et al., 1995; Spetea et al., 1998; Schmidt
t al., 2002; Thompson et al., 2004; Crooks et al., 2006). A
epresentative example is the comparison of binding afﬁni-
ies (Ki values in nM) of oxymorphone (::=0.97:80.5:61.6)
Lattanzi et al., 2005) with its 3-methoxy analogue oxycodone
::=43.6:1087:2658) (Spetea et al., 2005). This phenomenon
as also described for morphine having a methylated (i.e. codeine)
r glucuronidated (i.e.morphine-3-glucoronide) hydroxyl group at
osition 3 (Pasternak et al., 1987; Mignat et al., 1995; Thompson et
l., 2004).
Similar to the structurally related derivatives, 14-MM and 14-
MO, compound 1 is characterized by agonist activity in vitro
nd in vivo, while exhibiting a distinct functional proﬁle. In in
itro [35S]GTPS binding assays, among all investigated opioid lig-
nds, compound 1 was shown to be the most potent agonist in
-protein activation having a 23-fold greater ED50 value than that
f the standard opioid agonist DAMGO, and producing 85% of the
aximum stimulation observed with DAMGO. Although it was as
fﬁcacious as morphine in stimulating [35S]GTPS binding, com-
ound 1 proved to be considerably more potent by more than
0-fold. Comparable ED50 and Emax values to the earlier reported
Spetea et al., 2003) were determined in this study for 14-MM-
timulated [35S]GTPS binding in rat brain membranes. Notably,
ere we also report the ﬁrst data on stimulation of [35S]GTPS
inding by 14-OMO. 14-OMO activated G-proteins as indicated
y the concentration-dependent increases in [35S]GTPS bind-
ng showing over 13-fold greater potency than DAMGO, while
xhibiting comparable efﬁcacy. We have also established that
4-OMO-stimulated [35S]GTPS binding is a  opioid receptor-
ediated event like that shown by 14-MM. The enhanced agonist
otency of 14-OMO compared to DAMGO as well as to morphine
etermined by [35S]GTPS binding assays is in agreement with
harmacological ﬁndings in in vitro bioassays using mouse vas
eferens (MVD), guinea pig ileum (GPI) and rat vas deferens prepa-
ations (Spetea et al., 2004a; Lattanzi et al., 2005; Riba et al.,
010).
In vitro, compound 1 activated G-proteins by speciﬁc stimula-
ion of  opioid receptors in rat brain membranes. This has been
emonstrated based on reversibility of the increase of [35S]GTPS
inding by compound 1 in the presence of the selective  opioid
eceptor antagonist CTAP (Kramer et al., 1989) and the lack of effect
f NTI (Portoghese et al., 1988a,b) and nor-NBI (Portoghese et al.,
987), as selective antagonists at  and  opioid receptors, respec-
ively. CTAP (1 and 10M), NTI (10nM) and nor-BNI (100nM) at
ested concentrations blocked stimulation of [35S]GTPS binding
y opioid agonists selective at  (DAMGO, Fig. 4),  ([d-Pen2, d-
en5]enkephalin) and  opioid receptors (U50,488H), respectively
Mizoguchi et al., 2000).
Based on in vitro functional results, the presence of a benzyl
roup in position 5 in compound 1 yielded a novel opioid agonist,
isplaying a 5-fold increase in potency compared to its 5-methyl
nalogue 14-MM, while it appears to be less efﬁcacious in stimu-
ating [35S]GTPS binding. Although the afﬁnity of analogue 1 for
pioid receptors is essentially not different from that of 14-MM,
t is possible that the presence of an arylalkyl group like benzyl at
osition 5 increases the potency of this agonist. A similar proﬁle
as observed when comparing agonist activities of the 5-benzyl
t
g
l
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erivative 1 to its 5-unsubstituted analogue 14-OMO. Methyla-
ion at position 5 of 14-OMO resulted in 14-MM, which shows
ess than 3-fold decrease in potency and similar maximal stimu-
ation of [35S]GTPS binding. The present observations on 14-MM
nd 14-OMO as potent agonists corroborate with described in vitro
ctivities in MVD, GPI and RVD bioassays (Spetea et al., 2004a;
attanzi et al., 2005; Riba et al., 2010).
In vivo, compound 1 appeared to be a potent opioid agonist by
xhibiting antinociceptive activity after systemic s.c. administra-
ion inmousemodels of nociceptivepain. Its antinociceptive effects
ere reversed by the opioid antagonist naloxone, supporting
n opioid receptor-mediated mechanism of action. In both hot-
late and tail-ﬂick tests, compound 1 produced a dose-dependent
ncrease in withdrawal latencies in response to a thermal stimu-
us giving ED50 values in the g range, i.e. 0.053 and 0.043mg/kg.
or comparison, s.c. morphine showed ED50 values of 2.63 and
.29mg/kg, respectively, in the two nociceptive assessments.
The antinociceptive potency of compound 1 was found to be
nly 1.9- and 1.5-fold lower than that of 14-MM in the hot-plate
nd tail-ﬂick tests, respectively, and it was 50-fold higher than that
f the ‘gold standard painkiller’ morphine. Thus, replacement of
he 5-methyl group in 14-MM with a benzyl substituent appears
o be well tolerated by giving rise to a highly potent and efﬁca-
iousantinociceptiveagent.Also, the introductionof abenzyl group
t position 5 in 14-OMO, affording compound 1, produced only a
odest change (3-fold decrease) in antinociceptive potency. The
AR observations derived in this study from the in vivo pharma-
ological ﬁndings on antinociceptive properties are in qualitative
greement with the in vitro opioid activities of the investigated
pioid morphinans.
 Opioid analgesics including morphine, codeine, oxycodone
nd fentanyl are known to depress motor activity, a side effect
hat limits their usefulness (Hayes and Tyers, 1983; Bowdle, 1998;
eert and Vermeirsch, 2005). To further address the behavioural
onsequences of the  receptor agonist proﬁle exhibited by the 5-
enzyl analogue of 14-MM, its effects on motor coordination using
he rotarod test were assessed across an antinociceptive effective
ange. In addition, the ﬁrst behavioural data on alterations inmotor
unction following systemic s.c. administration of 14-MM and 14-
MO are reported.
Results from behavioural investigations have shown that s.c.
osing of compound 1 to mice did not signiﬁcantly affect the
erformance in the rotarod test over the analgesic dose range
f 0.025–0.2mg/kg. By comparison at equianalgesic doses, sys-
emic morphine caused dose-dependent suppressive effects on
otor coordination with signiﬁcance at 10mg/kg, a ﬁnding con-
istent with previous reports (Gallantine and Meert, 2005; Jones
t al., 2005; Meert and Vermeirsch, 2005). Dosages that pro-
uce full antinociceptive efﬁcacy of the  opioid agonists 14-MM
0.1mg/kg) and14-OMO(0.06mg/kg)werealsoobserved todimin-
sh motor ability in the rotarod test. The mechanism responsible
or the impairment of normal motor function has been proposed
o be linked to the  opioid receptor activation in the basal gan-
lia, nucleus raphe pontis, periaqueductal gray and locus coeruleus
Havemann et al., 1980, 1982; Vankova et al., 1996; Bowdle, 1998).
utcomes of the rotarod experiments compiled with nociceptive
ehaviour ﬁndings indicated that replacing the 5-methyl group
ith a benzyl substituent in 14-MM led to an opioid ligand, which
chieves antinociceptive efﬁcacy at doses that do not signiﬁcantly
nﬂuence motor activity.We experimentally determined the physicochemical proper-
ies of compound 1 and found that the substitution of the methyl
roup in position 5 in 14-MM with a benzyl group leads to a more
iphophilic molecule, while also showing increased liphophilicity
ompared to its 5-unsubstituted analogue 14-OMO. Thus, com-
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ound 1 which displays considerable higher liphophilicity than
4-MM, 14-OMOandmorphinemay represent a feasible candidate
or oral and/or transdermal delivery.
In summary, we have described the synthesis and pharmaco-
ogical characterization of a novel  opioid receptor ligand, the
-benzyl analogue of 14-MM, which emerged as a high afﬁnity
nd potent  opioid antinociceptive agent with reduced propen-
ity to cause unwanted motor impairment. Our ﬁndings revealed
hat targeting position 5 represents a viable approach for tuning
he pharmacological properties of this class of opioids. The results
f the present work complement and sharpen the understanding
hat appropriate molecular manipulations of the morphinan tem-
late could afford opioid ligands that besides their scientiﬁc value
s pharmacological tools, may also have the potential of emerging
s novel analgesics with fewer side effects compared to currently
vailable treatments.
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